Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 28, 2020; 26(36): 5463-5473
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5463
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5463
Major gastrointestinal bleeding and antithrombotics: Characteristics and management
Jacques Bouget, EA 7449 REPERES, Pharmacoepidemiology and Health Services Research, Univ Rennes, Rennes 35000, France
Damien Viglino, Emergency Department and Mobile Intensive Care Unit-HP2 Laboratory INSERM U1042, University Grenoble Alps, La Tronche 38700, France
Quentin Yvetot, Emergency Department, CHU Rennes, Rennes 3500, France
Emmanuel Oger, EA 7449 REPERES, Université de Rennes 1, Rennes 35000, France
Author contributions: Oger E was the guarantor; Oger E and Bouget J designed the study; Bouget J, Viglino D, and Yvetot Q participated in the acquisition of the data; Oger E and Bouget J participated in the analysis and interpretation of data, and drafted the initial manuscript; Viglino D and Yvetot Q revised the article critically for important intellectual content.
Supported by National Clinical Research Hospital Program of the French Ministry of Health , No. PHRC-12-009-0243 .
Institutional review board statement: The study was reviewed and approved by Rennes University hospital Review Board. The study received regulatory approval (CNIL, DR-2013-488 with subsequent substantial changes DR-2016-489).
Informed consent statement: No informed and signed consent was needed for the basic survey.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: Requests for anonymized data will be considered by Professor Bouget, jacques.bouget@univ-rennes1.fr.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Emmanuel Oger, MD, PhD, Professor, EA 7449 REPERES, Université de Rennes 1, Bat 6, Campus Santé Villejean, 2 avenue Professeur Bernard, Rennes 35000, France. emmanuel.oger@univ-rennes1.fr
Received: June 9, 2020
Peer-review started: June 9, 2020
First decision: July 29, 2020
Revised: July 30, 2020
Accepted: August 29, 2020
Article in press: August 29, 2020
Published online: September 28, 2020
Processing time: 106 Days and 20.6 Hours
Peer-review started: June 9, 2020
First decision: July 29, 2020
Revised: July 30, 2020
Accepted: August 29, 2020
Article in press: August 29, 2020
Published online: September 28, 2020
Processing time: 106 Days and 20.6 Hours
Core Tip
Core tip: A large population requires long-term treatment with antithrombotics and gastrointestinal (GI) bleeding is the commonest bleeding manifestation. However, there are few reports on major GI bleeding among patients receiving an antithrombotic. We prospectively identified 1080 adult patients consecutively referred for major GI bleeding to emergency departments in two tertiary care hospitals between January 2013 and December 2015 while receiving an antithrombotic. Based on these data, we described clinical characteristics, bleeding locations, management and in-hospital mortality related to these events.